Greenway Therapeutix CEO, Dr. Michael Milane presents at the 2019 Autumn Dermatology Conference
New York, NY, November 04, 2019 – Greenway Therapeutix, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was at the 2019 Autumn Dermatology Conference in New York.
The company’s CEO, Dr. Michael Milane, presented educational information in better understanding the human internal Endocannabinoid systems and the associated inflammatory pathways. This was further expanded to how Cannabinoids work on the skin and the specific associated inflammatory cascades of immune factors.
Unique to this presentation and as one of the first times this data has been world released, Dr. Milane presented recent human clinical data on a few clinical observational cases where Atopic Dermatitis, Periorbital Dermatitis and itch have recently been observed to have high levels of efficacy with a novel formulation of Nano CBD Cream.
There was one clinical observational case presented on Atypical Rosacea, where the patient had failed currently prescribed treatments and responded positively with a significant reduction of symptoms in 10 days with monotherapy treatment on Nano CBD Cream. The patient was followed for 3 months of treatment with continued clearance on this regiment. This was the first clinical data ever presented on short- and long-term safety and efficacy of treatment of Rosacea with CBD.
In addition to the scientific content, Dr. Milane covered the history of Cannabis as it has been used for medicine, expanding back to 2700 BC in China and spreading through multiple cultures, such as the Egyptians, Romans and to the Americas for multiple conditions.
The Program Director, Dr. Orit Markowitz, a Board-Certified Dermatologist from New York, indicated that there is surely a need for more education, data and larger studies on safety and efficacy of these conditions with CBD use for multiple skin conditions.
About Greenway Therapeutix
Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.
Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.
For more information, visit www.greenwaytherapeutix.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.